Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
UBS
US Department of Justice
Queensland Health
US Army
Teva
Dow
Julphar

Generated: May 21, 2018

DrugPatentWatch Database Preview

ELOXATIN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Eloxatin patents expire, and when can generic versions of Eloxatin launch?

Eloxatin is a drug marketed by Sanofi Aventis Us and is included in two NDAs.

The generic ingredient in ELOXATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.

US Patents and Regulatory Information for ELOXATIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021492-001 Aug 9, 2002 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-002 Jan 31, 2005 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-001 Jan 31, 2005 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021492-002 Aug 9, 2002 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for ELOXATIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-001 Jan 31, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021492-001 Aug 9, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021492-001 Aug 9, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-003 Nov 17, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ELOXATIN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 5 mg/mL, 40 mL vial ➤ Subscribe 2011-03-23
➤ Subscribe Injection 200 mg/40 mL ➤ Subscribe 2007-07-16
➤ Subscribe Injection 5 mg/mL, 10 mL and 20 mL vials ➤ Subscribe 2007-02-09
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 2007-02-09

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Colorcon
Deloitte
Accenture
Cantor Fitzgerald
Boehringer Ingelheim
Dow
Farmers Insurance
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.